The Relationship Between DPAV Sensitivity and Three Prognostic Factors
| Three Prognostic Factors . | 3-yr EFS (95% confidence intervals) . | No. of Patients for DPAV Sensitivity . | Contingency Table Analysis . | ||
|---|---|---|---|---|---|
| . | . | SS . | IS . | RR . | . |
| Immunologic classification | |||||
| cALL (n = 143) | 0.722 (0.632-0.811) | 34 | 62 | 47 | |
| T-ALL (n = 21) | 0.501 (0.237-0.766) | 3 | 6 | 12 | |
| mix ALL (n = 27) | 0.575 (0.285-0.865) | 4 | 10 | 13 | |
| uALL (n = 5) | 0.600 (0.171-1.000) | 1 | 2 | 2 | P = .391 |
| Age | |||||
| Infant (<1 yr old, n = 10) | 0.111 (0-0.316)5-150 | 2 | 2 | 6 | |
| 1-9 yr old (n = 127) | 0.772 (0.678-0.866) | 28 | 60 | 39 | |
| >9 yr old (n = 59) | 0.607 (0.461-0.753) | 12 | 18 | 29 | P = .062 |
| Initial WBC count (/μL) | |||||
| <10,000 (n = 88) | 0.747 (0.636-0.857) | 14 | 34 | 40 | |
| 10,000-50,000 (n = 66) | 0.738 (0.594-0.882) | 18 | 29 | 19 | |
| >50,000 (n = 42) | 0.421 (0.244-0.598) | 10 | 17 | 15 | P = .239 |
| Three Prognostic Factors . | 3-yr EFS (95% confidence intervals) . | No. of Patients for DPAV Sensitivity . | Contingency Table Analysis . | ||
|---|---|---|---|---|---|
| . | . | SS . | IS . | RR . | . |
| Immunologic classification | |||||
| cALL (n = 143) | 0.722 (0.632-0.811) | 34 | 62 | 47 | |
| T-ALL (n = 21) | 0.501 (0.237-0.766) | 3 | 6 | 12 | |
| mix ALL (n = 27) | 0.575 (0.285-0.865) | 4 | 10 | 13 | |
| uALL (n = 5) | 0.600 (0.171-1.000) | 1 | 2 | 2 | P = .391 |
| Age | |||||
| Infant (<1 yr old, n = 10) | 0.111 (0-0.316)5-150 | 2 | 2 | 6 | |
| 1-9 yr old (n = 127) | 0.772 (0.678-0.866) | 28 | 60 | 39 | |
| >9 yr old (n = 59) | 0.607 (0.461-0.753) | 12 | 18 | 29 | P = .062 |
| Initial WBC count (/μL) | |||||
| <10,000 (n = 88) | 0.747 (0.636-0.857) | 14 | 34 | 40 | |
| 10,000-50,000 (n = 66) | 0.738 (0.594-0.882) | 18 | 29 | 19 | |
| >50,000 (n = 42) | 0.421 (0.244-0.598) | 10 | 17 | 15 | P = .239 |
Abbreviations: SS (super sensitivity), sensitive to all four drugs (Dex, Pred, ASP, VCR); IS (intermediate sensitivity), sensitive to two or three of the four drugs; RR (relative resistance), sensitive to one or none of the four drugs.
Two-year EFS.